Brain Cancer clinical trials in Nebraska

10 actively recruiting brain cancer trials at 6 sites across Nebraska.

Data from ClinicalTrials.gov · last refreshed 2026-05-25

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03418961

Sites in Nebraska:

CHI Health Saint Francis — Grand Island, Nebraska
Heartland Hematology and Oncology — Kearney, Nebraska
CHI Health Good Samaritan — Kearney, Nebraska
Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
Alegent Health Immanuel Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology

NCT ID: NCT06500455

Sites in Nebraska:

Nebraska Medicine-Bellevue — Bellevue, Nebraska
Nebraska Medicine-Village Pointe — Omaha, Nebraska
University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04166409

Sites in Nebraska:

Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …

Sponsor: Children's Oncology Group

NCT ID: NCT05382338

Sites in Nebraska:

Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …

Sponsor: Children's Oncology Group

NCT ID: NCT04684368

Sites in Nebraska:

Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05099003

Sites in Nebraska:

Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: * Progression-free and overall surv…

Sponsor: Aveta Biomics, Inc.

NCT ID: NCT06011109

Sites in Nebraska:

University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.

Sponsor: University of Nebraska

NCT ID: NCT04222062

Sites in Nebraska:

University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

A Study Utilizing Escitalopram in Glioma Patients

Glioma is a cancer of glial cells, a class of tissue supporting neuronal function in the brain. As many as 85% of glioma patients experience cognitive impairment. This is not only from direct tumor involvement, but also from therapy such a…

Sponsor: University of Nebraska

NCT ID: NCT03728673

Sites in Nebraska:

University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Nebraska:

Massive Bio SYNERGY-AI site — Omaha, Nebraska

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25